Blood Biomarkers and Gut Microbiota for Pancreatic Cancer Risk in Chronic Pancreatitis

Official record

Identifier

NCT07762950

Recruiting locations

Locations are not included in the offline baseline for this record. Open the official record to see the current site list.

Interventions studied

Not provided in the official record

Lead sponsor

Changhai Hospital

Target enrolment

800 participants

Study type

OBSERVATIONAL

Phase

Not provided in the official record

Status

Not yet recruiting

First posted

Aug 13, 2026

Last updated on the registry

Aug 13, 2026

Age

18 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Adults aged 18 years or older.
* Able to understand the study procedures and provide written informed consent.
* Healthy controls: participants without a known history of chronic pancreatitis or pancreatic cancer.
* Chronic pancreatitis cohort: participants diagnosed with chronic pancreatitis according to clinical guidelines, based on clinical, imaging, and/or genetic information.
* Pancreatic ductal adenocarcinoma cohort: participants with newly diagnosed pancreatic ductal adenocarcinoma based on clinical, imaging, and/or pathological evaluation.
* Willing to provide blood samples and relevant clinical information.
* For participants with chronic pancreatitis, willing to undergo longitudinal follow-up approximately every 6 to 12 months.

Exclusion Criteria:

* Unable or unwilling to provide written informed consent.
* Unable to provide required clinical information or biological samples.
* Prior diagnosis of another active malignant tumor, except adequately treated non-melanoma skin cancer or carcinoma in situ, if considered not to affect study participation by the investigator.
* Current severe acute infection or other serious medical condition that, in the investigator's judgment, may interfere with study participation or interpretation of immune-related analyses.
* Use of systemic immunosuppressive therapy or immunotherapy within a period considered clinically relevant by the investigator.
* Any condition that, in the investigator's judgment, makes the participant unsuitable for this study.

Indexed under

Pancreatic Cancer